|
|
Volumn 23, Issue 8, 2005, Pages 934-
|
|
No pain, no gain?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANALGESIC AGENT;
ANTICONVULSIVE AGENT;
ANTIDEPRESSANT AGENT;
BEXAROTENE;
CYCLOOXYGENASE 2 INHIBITOR;
MORPHINE SULFATE;
NALTREXONE;
NALTREXONE PLUS OXYCODONE;
NONSTEROID ANTIINFLAMMATORY AGENT;
OMEGA CONOTOXIN MVIIA;
OPIATE DERIVATIVE;
OXYCODONE;
OXYTREX;
PREGABALIN;
PTI 901;
UNCLASSIFIED DRUG;
CHRONIC PAIN;
CLINICAL TRIAL;
DIZZINESS;
DRUG APPROVAL;
DRUG COST;
DRUG EFFECT;
DRUG EFFICACY;
DRUG INDICATION;
DRUG MARKETING;
DRUG USE;
HUMAN;
INVESTMENT;
MONEY;
NAUSEA;
PRIORITY JOURNAL;
PROFIT;
RESPIRATION DEPRESSION;
SHORT SURVEY;
ANALGESICS;
BIOTECHNOLOGY;
COST-BENEFIT ANALYSIS;
DECISION SUPPORT TECHNIQUES;
DRUG INDUSTRY;
INVESTMENTS;
OWNERSHIP;
UNITED STATES;
|
|
EID: 23444444018
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt0805-934 Document Type: Short Survey |
|
Times cited : (5)
|
|
References (1)
|
